<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>C-type natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (CNP) plays a critical role in endochondral ossification through guanylyl cyclase-B (GC-B), a natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor subtype </plain></SENT>
<SENT sid="1" pm="."><plain>Cartilage-specific overexpression of CNP enhances skeletal growth and rescues the <z:hpo ids='HP_0003510'>dwarfism</z:hpo> in a transgenic <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> model with constitutive active mutation of fibroblast growth factor receptor-3 </plain></SENT>
<SENT sid="2" pm="."><plain>For future clinical application, the efficacy of CNP administration on skeletal growth must be evaluated </plain></SENT>
<SENT sid="3" pm="."><plain>Due to the high clearance of CNP, maintaining a high concentration is technically difficult </plain></SENT>
<SENT sid="4" pm="."><plain>However, to model high blood CNP concentration, we established a liver-targeted CNP-overexpressing transgenic mouse (SAP-CNP tgm) </plain></SENT>
<SENT sid="5" pm="."><plain>SAP-CNP tgm exhibited skeletal <z:hpo ids='HP_0001548'>overgrowth</z:hpo> in proportion to the blood CNP concentration and revealed phenotypes of systemic stimulation of cartilage bones, including limbs, paws, costal bones, spine, and skull </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, in SAP-CNP tgm, the size of the foramen magnum, the insufficient formation of which results in cervico-medullary compression in <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e>, also showed significant increase </plain></SENT>
<SENT sid="7" pm="."><plain>CNP primarily activates GC-B, but under high concentrations it cross-reacts with guanylyl cyclase-A (GC-A), a natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> receptor subtype of atrial natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> (ANP) and brain natriuretic <z:chebi fb="7" ids="16670">peptides</z:chebi> (BNP) </plain></SENT>
<SENT sid="8" pm="."><plain>Although activation of GC-A could alter cardiovascular homeostasis, leading to <z:hpo ids='HP_0002615'>hypotension</z:hpo> and heart weight reduction, the skeletal <z:hpo ids='HP_0001548'>overgrowth</z:hpo> phenotype in the line of SAP-CNP tgm with mild overexpression of CNP did not accompany decrease of systolic blood pressure or heart weight </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that CNP administration stimulates skeletal growth without adverse cardiovascular effect, and thus CNP could be a promising remedy targeting <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> </plain></SENT>
</text></document>